venous thrombosis. Other associated factors include cyclosporin, diabetes, high haematocrit, and factor V Background. Renal-vein thrombosis (RVT ) is an infrequent event that accounts for a high proportion of Leiden mutation, but commonly no aetiological factor can be identified. RVT usually results in loss of the early renal allograft losses, since graft failure secondary to acute irreversible rejection is now relatively rare. graft because of delay in diagnosis and infarction of the kidney. Occasionally, RVT can be life-threatening The cause of RVT may be related to technical problems, clotting disorders, diabetes, or cyclosporin, but with graft rupture and haemorrhage. From July 1991, aspirin was introduced in our unit for 1 month postis often difficult to define. Methods. This retrospective study was performed to transplant in an attempt to reduce the incidence of RVT. examine the influence of aspirin on the incidence of RVT in cadaveric and living-related renal transplant recipients receiving cyclosporin-based triple immuno-Subjects and methods RVT. In July 1991, aspirin (75 mg o.d. starting immedi-listed, was ambiguous, or was recorded as RVT, were examately before and continuing for 1 month post-ined for clinical and pathological evidence of RVT. Complete transplant) was introduced as routine prophylaxis information was obtained for 66 records; there were no against RVT. Prior to this, aspirin prophylaxis was missing records. Information was retrieved from the patients' not used. notes, including operative details from the hand-written and
Introduction
For comparison, two 6-year periods were chosen, from July 1985 to June 1991 and from July 1991 to June 1997.
Renal-vein thrombosis (RVT ) is a rare complication Living related and cadaveric transplants and first and subof renal transplantation but a common cause of early sequent transplants were included in the study, giving a total graft loss. It is reported to occur with an incidence of of 955 transplants. Cyclosporin-based immunosuppression between 0.4% [1] and 6% [2] of all renal allografts. was given throughout this time as triple therapy, using from October 1992 to September 1994. In July 1991, aspirin graft). Five patients were pre-dialysis, but close to endwas introduced as prophylaxis for all patients undergoing stage renal failure, at the time of transplantation. The renal transplantation in an attempt to reduce the incidence thrombosis occurred at a mean of 6.6 days postof RVT. The standard dose was 75 mg once daily for 1 transplant (range 2-16 days). Mean recipient age was month post-transplant. Patients who were considered 'high 45 years (range 22-68 years), which was the same for risk' because of a history of thrombosis, diabetes, peripheral non-RVT recipients (45.3 years) and 19 recipients were vascular disease, or other vascular disease were continued male. Four patients had episodes of previous thromon aspirin long-term. Patients with previous renal artery or boses including deep-venous thrombosis (DVT ) and vein thrombosis were given 150 mg of aspirin per day and pulmonary embolus (PE ) (one), retinal-vein occlusion continued on aspirin long-term. Ranitidine was given to all patients for 6 months post-transplant for gastric protection (one), and clotted haemodialysis access (two). Three against high-dose steroids, but this probably also minimized of these patients were on maintenance oral antithe risk of gastric irritation from aspirin. coagulation and this was reversed before transplantaNuclear renogram was used as the mode of imaging of tion, although aspirin was given to the patient with a graft perfusion in most early cases of RVT. Colour duplex past history of DVT and PE (post-1991). PeriDoppler ultrasound has been used as the preferred investi-operative heparin was given to eight other patients, all gation since 1994. Renal core biopsy and fine-needle aspira-before 1991. Aspirin was given to the six patients who tion cytology was also utilized to confirm the diagnosis of sustained RVT after July 1991, including one patient graft infarction, but in some cases the diagnosis was only who also received low-dose heparin. apparent at operation. All graft nephrectomy specimens were
The underlying causes of renal failure in the patients subjected to pathological examination. Evidence of thrombus in the renal vein at operation and on histological examination who developed RVT are shown in Table 1 . Only diahas been used for inclusion in this study.
betic nephropathy was significantly more common in The cases of RVT could be subdivided into primary events, patients who suffered thrombosis. Known risk factors where the kidney was functioning and suddenly underwent for thrombosis were present pre-operatively in some thrombosis with no apparent cause, and secondary events, patients, detailed in Table 2. where there was identifiable underlying pathology. Those cases where severe acute rejection was the major histological 
Incidence of RVT (Figure 1)

Donor and recipient factors
Thirty-two cases of RVT occurred in cadaveric trans-NS, not statistically significant vs patients without thrombosis. ** incomplete data; *** mean values.
plants and one in a living related transplant (a third 
Low-dose aspirin as prophylaxis 1867
Clinical features twisting of the vein at implantation or on positioning of the kidney [4] . Small veins such as those in paediatric Some patients with RVT had concurrent thromboses kidneys or kidneys with multiple veins may also predisof other sites as detailed in Table 3 . Nineteen cases pose to thrombosis. Occasionally RVT is a consequence presented as primary RVT with no other pathology of extension of a lower limb venous thrombosis or present, either clinically or on histological examination. external iliac vein thrombosis which occludes the Secondary RVT included five cases with histological venous outflow of the graft and results in thrombosis. acute rejection, which may have been a contributory Following the introduction of cyclosporin, RVT was cause of RVT and graft loss. Four patients sustained felt to be more common with an incidence in one Unit peri-operative cardiac arrest, and despite resuscitation of 7.6% in patients taking cyclosporin, compared with the kidney thrombosed and infarcted, almost certainly 1.1% in patients on azathioprine and steroid [5] . Our secondary to hypoperfusion of the graft. In addition, own experience also suggested an increased incidence two patients sustained periods of hypotension which of thrombosis since the introduction of cyclosporin resulted in RVT. Technical problems with the renal [2] . Cyclosporin reduces renal blood flow [6 ], causes vein accounted for two cases and in another case a increased levels of thromboxane [7] , and reduces the clotting disorder was suspected.
production of prostacyclin by endothelial cells [8] . In Fine-needle aspiration cytology was performed on addition, high levels of cyclosporin may cause endo-11 transplants with deterioration in graft function, and thelial cell damage [9] and can enhance platelet this demonstrated necrotic kidney cells. Twelve 'Tru-aggregation [10], all potentially predisposing to RVT. cut' needle core biopsies were obtained from grafts Transplant patients taking cyclosporin have been with poor graft function; nine demonstrated renal shown to be hypercoagulable, compared to other surinfarction or necrosis, two were normal and one gical patients in the early post-operative period [11] . showed signs of rejection. All subsequently underwent
In the 499 transplants at our centre prior to the graft nephrectomy for RVT. Twenty-nine grafts were introduction of cyclosporin, there were only six cases pale and infarcted at the time of exploration. Three of RVT (1.2%). Graft vessel thrombosis has been kidneys were found to be grossly swollen with capsular reported with the use of OKT3 [12], but there are no splits and surrounding haematoma. In one case, throm-reported cases with tacrolimus or mycophenolate. One bectomy of the renal vein was attempted, but nephrec-of our patients on mycophenolate 3 g/day (in addition tomy of the infarcted kidney was performed the to cyclosporin and prednisolone) suffered RVT on following day. Thrombectomy of the external iliac vein aspirin, although post-operative cardiac arrest was the was performed as required. more likely underlying cause. Another risk factor for RVT includes transplantation into a diabetic recipient [13] and our findings agree Discussion with this ( Table 1) . Activated protein C resistance is strongly associated with the risk of venous thrombosis RVT is a rare complication of renal transplantation [14] and factor V Leiden mutation has been reported but a common cause of early graft loss, occurring with by our unit to explain 20% of primary RVT [15] . One a reported incidence between 0.4% [1] and 6% [2] . The study found that expression of plasminogen activator majority of RVT cases occur between 3 and 9 days inhibitor-1 by capillary endothelial cells is different in after transplantation [3] and in our series the mean transplant kidneys with RVT compared to normal time was 6.6 days. Commonly, no cause can be found, renal grafts [16 ] . although certain conditions have been associated with A clinical diagnosis of RVT can be made by the RVT. The main preventable factors are technical prob-presence of severe pain over the transplant and graft lem with the transplant renal vein such as damage to swelling associated with rapid deterioration in graft the vein at the time of retrieval, repair of the vein, or function. On examination, swelling and tenderness are often found over the kidney, sometimes associated with a swollen leg, from deep venous thrombosis or were related to platelet dysfunction and although there was no evidence to support the choice of low-dose Cause n aspirin, it was felt to have sufficient anti-platelet activity to be effective. The major defect caused by cyclosporin 1985; 17: 1973-1975 gastrointestinal bleeding has not been a problem in 
